article thumbnail

FIRST-LINE IBRANCEĀ® (PALBOCICLIB) COMBINATION THERAPY IN HR+, HER2- METASTATIC BREAST CANCER

The Pharma Data

IBRANCE may impair fertility in males and has the potential to cause genotoxicity. These findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research.

HR 52
article thumbnail

Treatment of Metastatic Triple-Negative Breast Cancer

The Pharma Data

In addition to multiple ongoing studies of SG in triple-negative breast cancer, it is being developed as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/HER 2-negative metastatic breast cancer, and metastatic non-small cell lung cancer, either as a monotherapy or in combination with other agents.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

TrodelvyĀ®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

Trodelvy is also being developed as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells.

HR 52
article thumbnail

TrodelvyĀ® for the Treatment of Metastatic Urothelial Cancer

The Pharma Data

Trodelvy is also being developed as an investigational treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells.

article thumbnail

Accelerating NDA filing through faster carcinogenicity assessment

Drug Discovery World

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) issues guidelines and develops testing strategies for evaluating carcinogenicity along with other risks such as genotoxicity, immunotoxicity, and reproductive toxicity.

article thumbnail

Let's Quit Sugar With Audiobook ā€“ Let's Quit Sugar

The Pharma Data

Following this program will help you lose weight fast, prevent yo-yoing, stabilize hormonal balance, and get back on track to leading a healthy life ā€“ all while never being hungry or having to go to the gym! Effects of glucose-to-fructose ratios in solutions on subjective satiety, food intake, and satiety hormones in young men.

Insulin 52